Rebulla and colleagues found lower post-transfusion platelet count increments with pathogen-reduced (PR) platelets compared with untreated platelets as well as increased red cell transfusions in recipients of PR platelets. They state pathogen reduction in infectious risk should be balanced against increased component utilization and its economic impact.
The Company's first product is the Platelet PGD Test – a rapid test for the detection of bacterial contamination in platelets.